

Product Datasheet

dTAGV-1 TFA

Catalog No. **BP-02376A** · CAS **2624313-15-9** · Form **salt** · **salt** · Physical state **other** · Color **White to off-white** · Version **1.0** · Revision **2026-09-11**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PROTACs; FKBP	Research area Cancer
--------------------------------	--------------------------------

Molecular formula **C₇₀H₉₁F₃N₆O₁₆S**

Molecular weight **1361.5620**

STRUCTURE



DESCRIPTION

dTAGV-1 TFA is a selective FKBP12 F36V PROTAC degrader. dTAGV-1 TFA induces rapid degradation of FKBP12 F36V-tagged oncogenic fusion proteins, triggering collapse of downstream cellular signaling pathways, reduced proliferative capacity of cancer cells, and decreased levels of target proteins. dTAGV-1 TFA is applicable to functional validation studies of cancer and undegradable oncoproteins .

BIOLOGICAL ACTIVITY

dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12F36V-Nluc in vivo.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : ≥ 100 mg/mL

REFERENCES

[1].Nabet B, et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature communications. 2020 Sep 18;11(1):4687.

[2].Zhu J, et al. FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation. Science advances. 2025 Nov 28;11(48):eadz2345.

[3].Prindle V, et al. Synthetic lethality of mRNA quality control complexes in cancer. Nature. 2025 Feb;638(8052):1095-1103.

Lot CoA and SDS are separate documents.